Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

导出 OA

翻译打印收藏纠错

第一作者： Ildiko,Lingvay

第一单位： Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas, USA.

作者： Ildiko,Lingvay ^[1] ; Kirstine,Brown-Frandsen ^[2] ; Helen M,Colhoun ^[3] ; John,Deanfield ^[4] ; Scott S,Emerson ^[5] ; Sille,Esbjerg ^[2] ; Søren,Hardt-Lindberg ^[2] ; G Kees,Hovingh ^[2] ; Steven E,Kahn ^[6] ; Robert F,Kushner ^[7] ; A Michael,Lincoff ^[8] ; Steven P,Marso ^[9] ; Tea Monk,Fries ^[2] ; Jorge,Plutzky ^[10] ; Donna H,Ryan ^[11] ; SELECT Study Group

作者单位： Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas, USA. ^[1] Novo Nordisk A/S, Søborg, Denmark. ^[2] Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ^[3] Farr Institute of Health Informatics Research at London, London, UK and National Institute for Cardiovascular Outcomes Research, University College London, London, UK. ^[4] Department of Biostatistics, University of Washington, Seattle, Washington, USA. ^[5] Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington, USA. ^[6] Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. ^[7] Cleveland Clinic Coordinating Center for Clinical Research (C5Research) and Department of Cardiovascular Medicine, Cleveland, Ohio, USA. ^[8] HCA Midwest Health Heart and Vascular Institute, Kansas City, Missouri, USA. ^[9] Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. ^[10] Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA. ^[11]